UK-based Amryt, a biopharmaceutical company focused on rare and orphan diseases, has announced the signing of four further distribution agreements for its Homozygous Familial Hypercholesterolaemia (HoFH) treatment, Lojuxta, across the Middle East. The agreements have been signed with Al Hafez Trading Establishment (Kuwait), Ebn Sina Medical (Qatar), Muscat Pharmacy and Stores (Oman), and Goro Healthcare (UAE/Bahrain). Amryt has signed nine distribution agreements for Lojuxta since November 2017. On the latest deals, Joe Wiley, the company's CEO, commented: “The Middle East has a higher HoFH patient population per capita than Europe and we look forward to working closely with our new distribution partners to improve patient outcomes.” An interview with Amryt's Dr. Joe Wiley will feature in the upcoming June issue of Pharmaceutical Executive.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.